Prange Anna, Bokhof Beate, Polzer Philipp, Tio Joke, Radke Isabel, Heidinger Oliver, Heindel Walter, Weigel Stefanie
Institute of Clinical Radiology and Reference Center for Mammography Muenster, University of Muenster and University Hospital Muenster, Germany.
Department of Gynecology and Obstetrics, University of Muenster and University Hospital Muenster, Germany.
Rofo. 2019 Feb;191(2):130-136. doi: 10.1055/a-0657-3970. Epub 2018 Aug 13.
Assessment of age group-dependent detection rates of invasive breast cancers among participants in mammography screening including the interval, classified into immunohistochemical subtypes indicating the intrinsic tumor aggressiveness.
The target population comprises women aged 50 - 69 years. All invasive breast cancers diagnosed in one screening (sc) unit during the implementation phase 1/2006 - 12/2010 or identified by the cancer registry during the biennial interval (iv) were categorized based on hormonal-receptor status (HR) and Her2-expression (Her2) into the following subtypes: a) HR+ Her2-, b) HR+ Her2 +, c) HR- Her2 + or d) HR- Her2- (triple-negative); Her2 + and triple-negative types were defined as aggressive. The calculated detection rates (DR, ‰) were based on 53 375 sc-examinations and for the interval on 52 887 sc-negative examinations.
The DRs of all subtypes were higher in screening versus the interval: (a) 4.95 ‰ (n = 264) vs. 1.00 ‰ (n = 53); b) 0.92 ‰ (n = 49) vs. 0.25 ‰ (n = 13); c) 0.36 ‰ (n = 19) vs. 0.06 ‰ (n = 3); d) 0.39 ‰ (n = 21) vs. 0.19 ‰ (n = 10). 77.4 ‰ (89/115) of all aggressive breast cancers including the following 2-year interval were diagnosed by screening. The sum of the DR of aggressive cancers was 1.67 ‰ in screening and 0.49 ‰ in the interval; the corresponding DRs for women aged 60 - 69 years [sc: 2.24 ‰ (51/22 814), iv: 0.58 ‰ (13/22 536)] were higher than among women aged 50 - 59 years [sc: 1.24 ‰ (38/30 561), iv: 0.43 ‰ (13/30 351)].
Screening has the potential for earlier diagnosis of aggressive tumor types as its detection rate is about three-fold higher compared to the interval. Within the target group, participants aged 60 - 69 years are at risk based on absolute numbers. They show a nearly two-fold higher detection rate of Her2-positive or triple-negative tumors compared to the age group 50 - 59 years.
· Her2-positive and triple-negative detection rates are higher in screening than in the interval.. · 77 % of aggressive subtypes are diagnosed by screening, 23 % during the 2-year interval.. · The detection rate is highest among women aged 60 - 69 years in screening..
· Prange A, Bokhof B, Polzer P et al. Higher Detection Rates of Biologically Aggressive Breast Cancers in Mammography Screening than in the Biennial Interval. Fortschr Röntgenstr 2019; 191: 130 - 136.
评估乳腺钼靶筛查参与者中不同年龄组浸润性乳腺癌的检出率，包括间期癌，并将其分为指示肿瘤内在侵袭性的免疫组织化学亚型。
目标人群为年龄在50-69岁的女性。在2006年1月至2010年12月实施阶段在一个筛查（sc）单位诊断出的所有浸润性乳腺癌，或在两年间期（iv）由癌症登记处确定的浸润性乳腺癌，根据激素受体状态（HR）和Her2表达（Her2）分为以下亚型：a）HR + Her2 -，b）HR + Her2 +，c）HR - Her2 +或d）HR - Her2 -（三阴性）；Her2 +和三阴性类型被定义为侵袭性。计算的检出率（DR，‰）基于53375次sc检查，间期癌的检出率基于52887次sc阴性检查。
所有亚型的检出率在筛查时均高于间期：（a）4.95‰（n = 264）对1.00‰（n = 53）；b）0.92‰（n = 49）对0.25‰（n = 13）；c）0.36‰（n = 19）对0.06‰（n = 3）；d）0.39‰（n = 21）对0.1
